Loading...

We've got a brand new version of Simply Wall St! Try it out

Kotra Industries Berhad

KLSE:KOTRA
Snowflake Description

Flawless balance sheet and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KOTRA
KLSE
MYR277M
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. MY
    3. ›
  3. Pharmaceuticals & Biotech
Last updated 2019/12/10 14:54
Company description

Kotra Industries Berhad, an investment holding company, develops, manufactures, and trades in pharmaceutical and healthcare products in Malaysia. The last earnings update was 12 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
KOTRA Share Price and Events
7 Day Returns
-6.4%
KLSE:KOTRA
-2.9%
MY Pharmaceuticals
-0%
MY Market
1 Year Returns
12.4%
KLSE:KOTRA
10.8%
MY Pharmaceuticals
-2.5%
MY Market
KOTRA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kotra Industries Berhad (KOTRA) -6.4% -5% 7.3% 12.4% 81.9% 63.2%
MY Pharmaceuticals -2.9% -1% 7.2% 10.8% 63.6% 70.8%
MY Market -0% -1.8% -0.3% -2.5% -7.4% -8.2%
1 Year Return vs Industry and Market
  • KOTRA outperformed the Pharmaceuticals industry which returned 10.8% over the past year.
  • KOTRA outperformed the Market in Malaysia which returned -2.5% over the past year.
Price Volatility
KOTRA
Industry
5yr Volatility vs Market

Value

 Is Kotra Industries Berhad undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Kotra Industries Berhad to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Kotra Industries Berhad.

KLSE:KOTRA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.3%
Perpetual Growth Rate 10-Year MY Government Bond Rate 3.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for KLSE:KOTRA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year MY Govt Bond Rate 3.4%
Equity Risk Premium S&P Global 7%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.685 (1 + (1- 24%) (15.14%)) 		0.842
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)		 0.84
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.42% + (0.842 * 6.96%) 		9.28%

Discounted Cash Flow Calculation for KLSE:KOTRA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Kotra Industries Berhad is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

KLSE:KOTRA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (MYR, Millions) Source Present Value
Discounted (@ 9.28%)
2020 29.55 Est @ 1.62% 27.04
2021 30.19 Est @ 2.16% 25.28
2022 30.95 Est @ 2.54% 23.72
2023 31.82 Est @ 2.8% 22.32
2024 32.77 Est @ 2.99% 21.03
2025 33.80 Est @ 3.12% 19.85
2026 34.88 Est @ 3.21% 18.74
2027 36.02 Est @ 3.27% 17.71
2028 37.22 Est @ 3.32% 16.75
2029 38.46 Est @ 3.35% 15.84
Present value of next 10 years cash flows MYR208.00
KLSE:KOTRA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= MYR38.46 × (1 + 3.42%) ÷ (9.28% – 3.42%) 		MYR679.13
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= MYR679.13 ÷ (1 + 9.28%)10 		MYR279.68
KLSE:KOTRA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= MYR208.00 + MYR279.68 		MYR487.68
Equity Value per Share
(MYR)		 = Total value / Shares Outstanding
= MYR487.68 / 144.90 		MYR3.37
KLSE:KOTRA Discount to Share Price
Calculation Result
Value per share (MYR) From above. MYR3.37
Current discount Discount to share price of MYR1.91
= -1 x (MYR1.91 - MYR3.37) / MYR3.37 		43.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Kotra Industries Berhad is available for.
Intrinsic value
43%
Share price is MYR1.91 vs Future cash flow value of MYR3.37
Current Discount Checks
For Kotra Industries Berhad to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Kotra Industries Berhad's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Kotra Industries Berhad's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kotra Industries Berhad's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kotra Industries Berhad's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
KLSE:KOTRA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in MYR MYR0.15
KLSE:KOTRA Share Price ** KLSE (2019-12-10) in MYR MYR1.91
Malaysia Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 13.85x
Malaysia Market PE Ratio Median Figure of 586 Publicly-Listed Companies 14.46x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kotra Industries Berhad.

KLSE:KOTRA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= KLSE:KOTRA Share Price ÷ EPS (both in MYR)

= 1.91 ÷ 0.15

 12.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kotra Industries Berhad is good value based on earnings compared to the MY Pharmaceuticals industry average.
  • Kotra Industries Berhad is good value based on earnings compared to the Malaysia market.
Price based on expected Growth
Does Kotra Industries Berhad's expected growth come at a high price?
Raw Data
KLSE:KOTRA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 12.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts		 Not available
Asia Pharmaceuticals Industry PEG Ratio Median Figure of 169 Publicly-Listed Pharmaceuticals Companies 1.34x
Malaysia Market PEG Ratio Median Figure of 261 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kotra Industries Berhad, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kotra Industries Berhad's assets?
Raw Data
KLSE:KOTRA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in MYR MYR1.27
KLSE:KOTRA Share Price * KLSE (2019-12-10) in MYR MYR1.91
Malaysia Pharmaceuticals Industry PB Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.22x
Malaysia Market PB Ratio Median Figure of 911 Publicly-Listed Companies 0.76x
KLSE:KOTRA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= KLSE:KOTRA Share Price ÷ Book Value per Share (both in MYR)

= 1.91 ÷ 1.27

 1.5x

* Primary Listing of Kotra Industries Berhad.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kotra Industries Berhad is overvalued based on assets compared to the MY Pharmaceuticals industry average.
Show me more potentially undervalued companies in the Pharmaceuticals industry
X
Value checks
We assess Kotra Industries Berhad's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
    5. Kotra Industries Berhad has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Kotra Industries Berhad expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kotra Industries Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.9%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kotra Industries Berhad expected to grow at an attractive rate?
  • Unable to compare Kotra Industries Berhad's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Kotra Industries Berhad's earnings growth to the Malaysia market average as no estimate data is available.
  • Unable to compare Kotra Industries Berhad's revenue growth to the Malaysia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
KLSE:KOTRA Future Growth Rates Data Sources
Data Point Source Value (per year)
Asia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.9%
Asia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 10.4%
Malaysia Market Earnings Growth Rate Market Cap Weighted Average 11%
Malaysia Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
KLSE:KOTRA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in MYR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
KLSE:KOTRA Future Estimates Data
Date (Data in MYR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
KLSE:KOTRA Past Financials Data
Date (Data in MYR Millions) Revenue Cash Flow Net Income *
2019-09-30 165 36 22
2019-06-30 173 37 22
2019-03-31 177 37 21
2018-12-31 181 37 20
2018-09-30 182 37 19
2018-06-30 178 36 16
2018-03-31 176 37 12
2017-12-31 177 33 13
2017-09-30 176 32 15
2017-06-30 166 34 12
2017-03-31 165 27 13
2016-12-31 162 23 9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Kotra Industries Berhad is high growth as no earnings estimate data is available.
  • Unable to determine if Kotra Industries Berhad is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
KLSE:KOTRA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Kotra Industries Berhad Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KLSE:KOTRA Future Estimates Data
Date (Data in MYR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
KLSE:KOTRA Past Financials Data
Date (Data in MYR Millions) EPS *
2019-09-30 0.15
2019-06-30 0.16
2019-03-31 0.16
2018-12-31 0.15
2018-09-30 0.14
2018-06-30 0.12
2018-03-31 0.09
2017-12-31 0.10
2017-09-30 0.11
2017-06-30 0.09
2017-03-31 0.10
2016-12-31 0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kotra Industries Berhad will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Kotra Industries Berhad is trading at Kotra Industries Berhad'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Kotra Industries Berhad's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Kotra Industries Berhad's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Asia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kotra Industries Berhad has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Kotra Industries Berhad performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kotra Industries Berhad's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kotra Industries Berhad has delivered over 20% year on year earnings growth in the past 5 years.
  • Kotra Industries Berhad's 1-year earnings growth is less than its 5-year average (13.3% vs 32.6%)
  • Kotra Industries Berhad's earnings growth has exceeded the MY Pharmaceuticals industry average in the past year (13.3% vs 1.2%).
Earnings and Revenue History
Kotra Industries Berhad's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kotra Industries Berhad Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

KLSE:KOTRA Past Revenue, Cash Flow and Net Income Data
Date (Data in MYR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 165.11 21.66 72.85
2019-06-30 172.55 22.20 72.85
2019-03-31 177.05 21.24 75.91
2018-12-31 180.88 19.74 75.91
2018-09-30 182.31 19.12 75.91
2018-06-30 178.48 15.75 75.91
2018-03-31 176.36 12.11 75.54
2017-12-31 177.02 13.02 75.54
2017-09-30 175.65 14.57 75.54
2017-06-30 166.37 12.40 75.54
2017-03-31 165.04 13.33 71.16
2016-12-31 162.08 9.42 71.16
2016-09-30 156.35 4.26 71.16
2016-06-30 160.23 7.76 71.16
2016-03-31 157.59 5.68 74.32
2015-12-31 150.73 5.74 74.32
2015-09-30 150.78 7.45 74.32
2015-06-30 145.17 1.06 74.32
2015-03-31 149.73 3.81 66.27
2014-12-31 157.56 8.53 66.27
2014-09-30 153.67 6.25 66.27
2014-06-30 147.37 5.66 66.27
2014-03-31 146.38 7.90 57.61
2013-12-31 140.70 6.04 57.61
2013-09-30 133.74 4.17 57.61
2013-06-30 131.29 3.69 57.61
2013-03-31 129.80 1.83 56.21
2012-12-31 121.19 -2.58 56.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Kotra Industries Berhad has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Kotra Industries Berhad used its assets more efficiently than the MY Pharmaceuticals industry average last year based on Return on Assets.
  • Kotra Industries Berhad has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Show me more strong past performing companies in the Pharmaceuticals industry
X
Past performance checks
We assess Kotra Industries Berhad's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kotra Industries Berhad has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Kotra Industries Berhad's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kotra Industries Berhad's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kotra Industries Berhad is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kotra Industries Berhad's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kotra Industries Berhad's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kotra Industries Berhad Company Filings, last reported 2 months ago.

KLSE:KOTRA Past Debt and Equity Data
Date (Data in MYR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 177.38 40.98 31.01
2019-06-30 172.16 44.30 29.18
2019-03-31 165.59 47.49 23.91
2018-12-31 164.62 50.67 27.62
2018-09-30 157.88 53.82 24.30
2018-06-30 153.25 57.25 21.31
2018-03-31 147.58 64.63 19.91
2017-12-31 149.11 63.59 16.04
2017-09-30 144.68 67.17 15.68
2017-06-30 142.08 72.96 17.30
2017-03-31 139.90 82.39 14.72
2016-12-31 137.51 82.44 14.05
2016-09-30 131.54 89.22 17.03
2016-06-30 131.21 95.60 16.77
2016-03-31 127.97 97.13 14.90
2015-12-31 126.84 98.67 16.17
2015-09-30 125.79 104.44 13.68
2015-06-30 121.74 102.83 12.03
2015-03-31 120.65 109.52 13.84
2014-12-31 119.49 113.15 13.35
2014-09-30 116.76 116.07 14.82
2014-06-30 119.06 119.39 13.65
2014-03-31 114.86 128.26 16.89
2013-12-31 108.61 128.74 14.41
2013-09-30 107.81 124.13 12.96
2013-06-30 107.98 126.03 16.57
2013-03-31 100.14 126.35 10.11
2012-12-31 96.54 127.41 8.37
  • Kotra Industries Berhad's level of debt (23.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (99.3% vs 23.1% today).
  • Debt is well covered by operating cash flow (88%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 13.2x coverage).
Show me more healthy companies in the Pharmaceuticals industry
X
Financial health checks
We assess Kotra Industries Berhad's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. Kotra Industries Berhad has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Kotra Industries Berhad's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.61%
Current annual income from Kotra Industries Berhad dividends.
If you bought MYR2,000 of Kotra Industries Berhad shares you are expected to receive MYR92 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Kotra Industries Berhad's pays a higher dividend yield than the bottom 25% of dividend payers in Malaysia (1.9%).
  • Kotra Industries Berhad's dividend is below the markets top 25% of dividend payers in Malaysia (4.8%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
KLSE:KOTRA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Malaysia Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.8%
Malaysia Market Average Dividend Yield Market Cap Weighted Average of 463 Stocks 3.6%
Malaysia Minimum Threshold Dividend Yield 10th Percentile 1.2%
Malaysia Bottom 25% Dividend Yield 25th Percentile 1.9%
Malaysia Top 25% Dividend Yield 75th Percentile 4.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

KLSE:KOTRA Future Dividends Estimate Data
Date (Data in MYR) Dividend per Share (annual) Avg. No. Analysts
KLSE:KOTRA Past Annualized Dividends Data
Date (Data in MYR) Dividend per share (annual) Avg. Yield (%)
2019-10-14 0.088 4.341
2019-05-21 0.060 3.341
2019-02-20 0.060 3.501
2018-10-09 0.060 3.519
2018-05-14 0.040 2.315
2018-02-15 0.040 2.281
2017-10-12 0.040 2.340
2017-05-19 0.040 2.148
2017-02-10 0.040 2.930
2009-08-26 0.000 0.000
2009-05-28 0.000 0.000
2009-02-27 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Kotra Industries Berhad has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Kotra Industries Berhad only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Kotra Industries Berhad's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.1x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kotra Industries Berhad's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kotra Industries Berhad afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. Kotra Industries Berhad has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Kotra Industries Berhad's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jimmy Piong
COMPENSATION MYR5,500
AGE 62
CEO Bio

Mr. Teck Onn Piong, also known as Jimmy serves as Managing Director of Kotra Industries Bhd. Mr. Piong started his career in the retail and wholesale pharmaceutical business at City Chemist & Asia Pharmacy. In January 1984, he joined KPM and started KOTRA's manufacturing department. He has been Executive Council Member of the Malaysian Organisation of Pharmaceutical Industries (MOPI) since 1998 and has been its Vice President since 2001. Mr. Piong has been Director of Kotra Industries Bhd since June 5, 2000. Mr. Piong graduated from the University of Wales in Cardiff, United Kingdom in 1982 with a Bachelor Degree of Science in Pharmacy.

CEO Compensation
  • Insufficient data for Jimmy to compare compensation growth.
  • Jimmy's remuneration is lower than average for companies of similar size in Malaysia.
Management Team Tenure

Average tenure and age of the Kotra Industries Berhad management team in years:

14.1
Average Tenure
59.5
Average Age
  • The average tenure for the Kotra Industries Berhad management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jimmy Piong

TITLE
MD & Director
COMPENSATION
MYR6K
AGE
62

Adeline Chin

TITLE
Chief Information Officer & Executive Director
AGE
62

Daniel Chua

TITLE
Chief Financial Officer
AGE
45
TENURE
16.4 yrs

Ming Cheah

TITLE
Chief Operating Officer
AGE
48
TENURE
14.1 yrs

Mein Hiew

TITLE
Chief Brand Officer
AGE
58
TENURE
19.8 yrs

Siew Chua

TITLE
Company Secretary
AGE
61
TENURE
8.9 yrs

Seok Tay

TITLE
Joint Secretary
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Kotra Industries Berhad board of directors in years:

11.2
Average Tenure
59.5
Average Age
  • The average tenure for the Kotra Industries Berhad board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jamaludin Bin Nasir

TITLE
Independent Non-Executive Chairman
COMPENSATION
MYR87K
AGE
59
TENURE
2.9 yrs

Jimmy Piong

TITLE
MD & Director
COMPENSATION
MYR6K
AGE
62
TENURE
19.5 yrs

Adeline Chin

TITLE
Chief Information Officer & Executive Director
AGE
62
TENURE
19.5 yrs

Min Lee

TITLE
Independent Non-Executive Director
COMPENSATION
MYR80K
AGE
60
TENURE
2.9 yrs

Vincent Piong

TITLE
Non-Independent Non-Executive Director
COMPENSATION
MYR19K
AGE
52
TENURE
19.5 yrs

Chee Piong

TITLE
Non Independent & Non Executive Director
COMPENSATION
MYR20K
AGE
40
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (MYR) Value (MYR)
X
Management checks
We assess Kotra Industries Berhad's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. Kotra Industries Berhad has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Kotra Industries Berhad, an investment holding company, develops, manufactures, and trades in pharmaceutical and healthcare products in Malaysia. It provides nutraceutical products, including various health supplement products under the Appeton brand for children, expectant mothers, and seniors. The company also offers various pharmaceutical products in the areas of pediatric care, anti-infective, gastroenterology, and dermatology in various dosage forms, such as tablets, capsules, creams, and ointments under the Axcel brand name; and sterile antibiotic injectables under the Vaxcel brand name. The company was founded in 1982 and is based in Melaka, Malaysia. Kotra Industries Berhad is a subsidiary of Piong Nam Kim Holdings Sdn. Bhd.

Details
Name: Kotra Industries Berhad
KOTRA
Exchange: KLSE
Founded: 1982
MYR276,760,304
144,900,683
Website: http://www.kotrapharma.com
Address: Kotra Industries Berhad
Cheng Industrial Estate,
No. 1, 2 & 3, Jalan TTC 12,
Melaka,
Melaka, 75250,
Malaysia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
KLSE KOTRA Ordinary Shares Bursa Malaysia MY MYR 21. Nov 2000
Number of employees
Current staff
Staff numbers
693
Kotra Industries Berhad employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/10 14:54
End of day share price update: 2019/12/10 00:00
Last estimates confirmation: 2019/08/22
Last earnings filing: 2019/11/28
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)